Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

Stopped The independent DSMB recommended that the study be stopped for futility following interim efficacy analysis.

Conditions

• Staphylococcus Aureus Bacteremia
• Staphylococcus Aureus Endocarditis

Interventions

• DRUG: Exebacase
• DRUG: Placebo

Sponsor

ContraFect